India's top court dismissed Swiss drugmaker Novartis' attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.
Novartis loses landmark India cancer drug patent case
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.